PAR-24-131: Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 17, 2025.
From the official notice on Grants.gov, last changed November 17, 2025. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44
- Clinical trialsNot allowed
- Funded byNHLBI, NIGMS, NIDDK
- Median yearly award$313,827
- Typical project length1 year
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under PAR-24-131 were run by National Heart Lung and Blood Institute (NHLBI, 6 projects), National Institute of General Medical Sciences (NIGMS, 4 projects), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 3 projects) and National Institute of Dental and Craniofacial Research (NIDCR, 2 projects), and 7 more. Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-131 in the NIH Guide.
Key dates
| Posted | April 25, 2024 |
|---|---|
| Deadline | November 17, 2025 |
| Archived by Grants.gov | November 18, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the money in the 21 programs behind this notice (74% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Notice of Funding Opportunity (NOFO), the National Institutes of Health (NIH) aims to facilitate the career development and transition of investigators new to entrepreneurship with an interest in small business by simultaneously supporting their entrepreneurial development and the conduct of research and development under their direction. This NOFO supports small business concerns (SBCs) in employing and developing researchers as entrepreneurial Program Directors/Principal Investigators (PDs/PIs). In addition to augmenting scientific research staff and supporting research and development efforts at SBCs, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Optimal PDs/PIs for this award are scientists and professionals with strong research, technology development, and/or healthcare delivery skills and experience, but limited entrepreneurial and independent research project leadership experience. PDs/PIs are expected to grow their entrepreneurial skillset while working in a small business to develop promising technologies and products that align with NIH's mission to improve health and save lives.
Funded under PAR-24-131 so far
NIH funded 24 projects under PAR-24-131 in fiscal 2025 to 2026, at 24 institutions. The median yearly award was $313,827.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Innovative glycan-specific reagents to accelerate the detection of disease biomarkers | Lectenz Bio, Inc. | 2026 | $1.0 million |
| Development of a Novel Integrin Antagonist for the Treatment of Pulmonary Hypertension | Lila Biologics, Inc. | 2026 | $605,981 |
| Smart Dental Implant(TM): Advanced Self-Powered Phototherapuetic Dental Implant | Leden LLC | 2026 | $306,084 |
| Real-Time Measurement of Mitochondrial Temperature with Fluorescent Nanodiamond | Adamas Nanotechnologies, Inc. | 2026 | $306,872 |
| Oxygen reducing microcapsules for in vitro control of hypoxia | Oxylo, Inc. | 2026 | $603,604 |
| Automating Quality to Accelerate Transformational Improvements in Care (AQUATIC) | Clairyon, Inc. | 2026 | $1.1 million |
| Development of First-in-Class, Non-Hormonal TDO2 Inhibitors for the Treatment of Uterine Fibroids | Evina Biosciences, Inc. | 2026 | $400,359 |
| Machine Learning-Driven Precision Dosing System for Improved Anticoagulation Therapy | Precisionbio Ai, LLC | 2026 | $374,472 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Biomedical Research and Research Training grants before
From fiscal 2021 to 2025, Biomedical Research and Research Training (93.859) awarded $15 billion across 11,631 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 186 | $290 million |
| Regents of the University of Michigan | Michigan | 226 | $268 million |
| University of California, San Diego | California | 198 | $264 million |
| Yale Univ | Connecticut | 195 | $250 million |
| University of Wisconsin System | Wisconsin | 169 | $241 million |
Other programs behind this notice
- Diabetes, Digestive, and Kidney Diseases Extramural Research
- Drug Use and Addiction Research Programs
- Child Health and Human Development Extramural Research
- Vision Research
- National Center for Advancing Translational Sciences
- Arthritis, Musculoskeletal and Skin Diseases Research
- Alcohol Research Programs
- Human Genome Research
- Environmental Health
- Research Related to Deafness and Communication Disorders
- Oral Diseases and Disorders Research
- Nursing Research
- Occupational Safety and Health Program
- Research and Training in Complementary and Integrative Health
- Medical Library Assistance
- NIEHS Superfund Hazardous Substances_Basic Research and Education
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-131 still open?
No. It closed on November 17, 2025.
Who can apply for Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed)?
Closed November 17, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-24-131?
NIH RePORTER lists 24 projects funded under PAR-24-131 in fiscal 2025 to 2026, at 24 institutions. The most were at Lectenz Bio, Inc., Lila Biologics, Inc., Leden LLC.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)